Skip to main content

Table 3 Radiologic response after completion of neoadjuvant therapy for patients with pancreatic adenocarcinoma

From: Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients

  Radiologic response
  Complete response Partial response Stable disease Progressive disease
Resectable 0% 11% 77% 11%
[0–0%] [8–16%] [62–89%] [4–19%]
I 2 = 0% I 2 = 10.6% I 2 = 85.12% I 2 = 82.31%
(n = 8) (n = 8) (n = 9) (n = 11)
Borderline resectable 1% 20% 56% 19%
[0–4%] [8–35%] [47–64%] [11–28%]
I 2 = 52.03% I 2 = 84.28% I 2 = 33.25% I 2 = 58.95%
(n = 8) (n = 8) (n = 8) (n = 9)
Locally advanced 1% 28% 48% 20%
[0–3%] [21–35%] [38–58%] [13–29%]
I 2 = 57.02% I 2 = 82.61% I 2 = 88.09% I 2 = 89.43%
(n = 17) (n = 19) (n = 17) (n = 18)
BR + LA 0% 20% 59% 14%
[0–1%] [11–31%] [49–69%] [8–22%]
I 2 = 7.57% I 2 = 84.70% I 2 = 76.89% I 2 = 72.59%
(n = 16) (n = 16) (n = 16) (n = 16)
All patients 0% 20% 59% 16%
[0–1%] [16–25%] [54–65%] [12–20%]
I 2 = 38.25% I 2 = 81.52% I 2 = 85.12% I 2 = 82.84%
(n = 52) (n = 56) (n = 56) (n = 62)
  1. Values in [] reflect the 95% confidence interval. I 2 is a quantitative indicator of heterogeneity among the studies, and n refers to the number of studies reporting the outcomes